4//SEC Filing
Landau Jeffrey B 4
Accession 0001610717-23-000298
CIK 0001501989other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 7:15 PM ET
Size
7.8 KB
Accession
0001610717-23-000298
Insider Transaction Report
Form 4
Landau Jeffrey B
Chief Business Officer
Transactions
- Sale
Common Stock
2023-09-22$1.30/sh−4,119$5,356→ 76,379 total - Award
Common Stock
2023-09-20+11,250→ 80,498 total
Holdings
- 3,180(indirect: By IRA)
Common Stock
- 4,500(indirect: By IRA)
Common Stock
Footnotes (3)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
- [F2]Includes 52,205 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
Documents
Issuer
CytomX Therapeutics, Inc.
CIK 0001501989
Entity typeother
Related Parties
1- filerCIK 0001918615
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 7:15 PM ET
- Size
- 7.8 KB